News
Public · Published
TD Cowen maintains Alnylam Pharmaceuticals at Buy, lowers price target to $354 from $482
TD Cowen kept its Buy rating on Alnylam Pharmaceuticals but cut its price target to $354 from $482, a 26.6% decrease. The new target implies 103.4% upside from the October 29 close of $174.
Published:
Updated:
What happened
TD Cowen kept its Buy rating on Alnylam Pharmaceuticals but cut its price target to $354 from $482, a 26.6% decrease. The new target implies 103.4% upside from the October 29 close of $174.
Confirmed
Global impact / market context
A lower price target still above the current price signals the analyst sees less upside but keeps a positive view. Investors reading this may question whether expected profits or drug prospects are weaker than previously assumed.
Analyst inference
Other recent analyst targets for Alnylam range from $199 to $320, all above the $174 close. TD Cowen's $354 target sits above that range, so it stands out as more optimistic than peers even after the cut.
Analyst inference
What to watch
- TD Cowen's $354 target implies 103.4% upside from the October 29 close of $174, so the gap between the target and the share price is the key figure to track. Confirmed
- Watch whether other firms revise their Alnylam targets after TD Cowen's cut, since five recent notes already range from $199 to $320 and could move in response. Proposed
- Track Alnylam's coming revenue and research spending updates, because a lower target can reflect softer expected profit, higher costs, or delayed drug progress that would show up there. Analyst inference
Evidence
- Original source link unavailable